ODAC to Discuss Exelixis' Application for Cabometyx Label Expansion
Portfolio Pulse from
The FDA has informed Exelixis that its supplemental New Drug Application (sNDA) for expanding the label of cabozantinib will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025.
November 27, 2024 | 5:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Exelixis' application for cabozantinib label expansion will be reviewed by the FDA's ODAC in March 2025, which could impact the drug's market potential.
The FDA's decision to review Exelixis' sNDA for cabozantinib could significantly impact the company's market potential if approved. However, the review is scheduled for March 2025, so the immediate short-term impact is neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100